<DOC>
	<DOCNO>NCT02441114</DOCNO>
	<brief_summary>This pilot study design evaluate pharmacokinetic characteristic fluticasone , salmeterol , tiotropium co-administration HCP 0910 ( Seretide 250 diskus ) HGP1011 ( Spiriva capsule inhalation ) prescribe concomitantly patient chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Pharmacokinetics Co-administration Seretide 250 Diskus ( HCP0910 ) Spiriva Capsule Inhalation ( HGP1011 )</brief_title>
	<detailed_description>Within 3 week prior first administration study drug , volunteer agree participation study write consent undergo screening , include physical examination clinical laboratory test etc , evaluate whether eligible participate study . Study drug administer 8 A.M. morning drug administration day , follow blood collection evaluation pharmacokinetics . The schedule increase dose proceed 14-day washout period .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Age 19 45 , healthy male subject ( screen ) Body weight 55kg 90kg , BMI ( Body Mass Index ) 18.0 27.0 Volunteer totally understand progress clinical trial , make decision free , signed consent Volunteer past present history disease liver include hepatitis virus carrier , kidney , Neurology , immunology , pulmonary , endocrine , hematooncology , cardiology , mental disorder Volunteer drug ( Aspirin , antibiotic ) hypersensitivity reaction Subject already participate trial 3 month Subject whole blood donation 2 month , component blood donation 1 month transfusion</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>